oncaspar lyophilizate for solution for i/m injection and infusion
les laboratoires servier industrie 905 - pegaspargase - lyophilizate for solution for i/m injection and infusion - 750iu/ml
oncaspar 750 u/ml powder for solution for injection/ infusion (iv/im)
les laboratoires servier; importer: servier philippines, inc.; distributor: zuellig pharma corporation - pegaspargase - powder for solution for injection/ infusion (iv/im) - 750 u/ml
oncaspar powder for solution for injection/infusion
les laboratoires servier, france - pegaspargase - powder for solution for injection/infusion - 750 iu/ml,
oncaspar i.v. infusion (オンキャスパー点滴静注用3750)
nihon servier co. ltd., - pegaspargase - injection
novomix 30 flexpen 3ml 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine 300u/3ml injection syringe
novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: hydrochloric acid; zinc; metacresol; water for injections; glycerol; sodium chloride; protamine sulfate; sodium hydroxide; dibasic sodium phosphate dihydrate; phenol - treatment of diabetes mellitus.
novomix 30 penfill 3ml 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine 300u/3ml injection cartridge
novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: zinc; dibasic sodium phosphate dihydrate; protamine sulfate; metacresol; sodium chloride; sodium hydroxide; glycerol; phenol; hydrochloric acid; water for injections - treatment of diabetes mellitus.
novorapid flexpen insulin aspart (rys) 300u/3ml injection multidose cartridge
novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; zinc; metacresol; dibasic sodium phosphate dihydrate; glycerol - treatment of diabetes mellitus.
novorapid penfill insulin aspart (rys) 300u/3ml injection cartridge
novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; zinc; dibasic sodium phosphate dihydrate; sodium hydroxide; glycerol; metacresol; sodium chloride; water for injections; hydrochloric acid - treatment of diabetes mellitus.
novorapid insulin aspart (rys) 100u/ml injection multidose vial
novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: water for injections; metacresol; glycerol; sodium chloride; dibasic sodium phosphate dihydrate; hydrochloric acid; sodium hydroxide; zinc; phenol - treatment of diabetes mellitus.
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate capsule, extended release
physicians total care, inc. - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e), amphetamine aspartate (unii: h527kap6l5) (amphetamine - unii:ck833kgx7e) - dextroamphetamine sulfate 2.5 mg - dextroamphetamine saccharate, amphetamine asparate monohydrate, dextroamphetamine sulfate and, amphetamine sulfate extended-release capsules is indicated for the treatment of attention deficit hyperactivity disorder (adhd). the efficacy of dextroamphetamine saccharate, amphetamine asparate monohydrate, dextroamphetamine sulfate and, amphetamine sulfate extended-release capsules in the treatment of adhd was established on the basis of two controlled trials in children aged 6 to 12, one controlled trial in adolescents aged 13 to 17, and one controlled trial in adults who met dsm-iv® criteria for adhd (see clinical pharmacology), along with extrapolation from the known efficacy of adderall® , the immediate-release formulation of this substance. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment